FDA status
Anti-doping (WADA)
Controlled substance
What is Thymosin Alpha-1?
Thymosin alpha 1 (Tα1) is a 28-amino-acid peptide. Its synthetic version, thymalfasin (INN), is sold internationally under the brand name Zadaxin. It isn’t a synthetic invention from scratch: it’s modelled on a natural fragment of prothymosin alpha, released when the enzyme legumain cleaves that larger parent molecule.
In the body, this fragment occurs naturally in the thymus, spleen, lungs, kidneys, brain, and blood, which is consistent with its role as a signaling peptide in immune regulation rather than a single-organ hormone.
Internationally, thymalfasin is a regulated drug, approved and marketed in dozens of countries for specific indications, historically hepatitis B and C, as a cancer adjuvant alongside chemotherapy or interferon, and for certain immune deficiencies. Each of these approvals sits behind disease-specific human trial data, discussed in the evidence section below.
In US wellness marketing, the same peptide is framed very differently, often positioned as a general “immune booster,” a longevity tool, or a long COVID remedy. That framing outruns the evidence: those uses are emerging or unsupported by dedicated human trials, not established indications.
The gap between regulated drug and wellness product
It’s worth separating two different things that share a name. Abroad, thymalfasin is a prescribed, regulated medicine with trial data tied to specific diseases.
In the US, where it isn’t FDA-approved, thymosin alpha 1 is sold as a compounded or “research” peptide, a very different regulatory and evidence context even though the molecule is the same. compounded peptides and US law
The underlying research base itself is modest by modern drug-development standards: a small number of foundational reviews published in 2010 and 2020, a handful of disease-specific randomized trials of varying size and age, and no large-scale modern US clinical trials.
That doesn’t make the compound fringe, but it does mean claims should be checked against what was actually studied, use case by use case. how we rate evidence
What the research shows
Strip away the marketing framing and the evidence for thymosin alpha 1 sorts into a clear hierarchy: strong for a couple of specific medical uses, thin or historical for several others, and essentially absent for the “immune support” framing most US consumers actually encounter.
Sepsis, Moderate
The strongest human data on thymosin alpha 1 comes from a meta-analysis of 12 controlled trials (n=1,480), which found a pooled mortality risk ratio of 0.68 (95% CI 0.59–0.78, p<0.00001) in patients receiving the peptide.
That’s a meaningful, statistically robust reduction in death risk across a sizeable pooled human sample, which is why sepsis sits at the top of the evidence hierarchy for this compound.
Cancer adjuvant, Moderate
A multicenter trial in 488 patients with metastatic melanoma tested thymosin alpha 1 combined with dacarbazine and interferon-alpha, alongside separate human data showing reduced chemotherapy-related toxicity in non-small cell lung cancer, hepatocellular carcinoma, breast cancer, and head and neck cancer.
The trial sizes here are respectable, but because thymosin alpha 1 was almost always given alongside chemotherapy or interferon rather than alone, it’s difficult to isolate how much of the benefit is attributable to the peptide itself.
Hepatitis B, Limited
Older human trials reported complete virological response in 40.6% of patients on thymosin alpha 1 versus 26.5% on standard regimens of the era. That result predates modern nucleoside analogs like entecavir, which now produce stronger outcomes with a simpler regimen. This is a historical use case rather than a current standard of care.
Hepatitis C, Limited
Similarly, thymosin alpha 1 was studied as an add-on to interferon therapy before direct-acting antivirals existed. Because those newer drugs now cure most hepatitis C cases outright, this application is effectively obsolete rather than something a clinician would reach for today.
HIV (adjunct with zidovudine/antiretrovirals), Limited
Small human trials paired thymosin alpha 1 with zidovudine and other antiretrovirals and reported modest immune improvements. These studies are limited in size and were conducted before modern antiretroviral regimens, so their relevance to current HIV care is narrow.
Vaccine adjuvant in elderly/immunocompromised patients, Limited
Human studies in older or immunocompromised patients suggest thymosin alpha 1 can improve antibody response to influenza and hepatitis B vaccines. The data is real but comes from small trials and represents a niche application rather than a widely adopted practice.
Primary immune deficiency / DiGeorge syndrome, Limited
Thymosin alpha 1 carries FDA orphan drug designation for conditions including DiGeorge syndrome, which reflects genuine clinical interest in the peptide for primary immune deficiencies. The underlying trial base supporting that designation, however, remains small.
COVID-19 / Long COVID, Emerging
Thymosin alpha 1 has been used clinically in China for COVID-19 since April 2020, and its known effects on T-cell maturation and cytokine signaling make it mechanistically plausible for long COVID. But no rigorous randomized trial or meta-analysis has specifically tested it for long COVID.
What’s driving current interest is mechanistic reasoning and anecdotal reports, not controlled human trial data.
General wellness / “immune support”, Emerging
This is the framing most US consumers encounter in marketing, and it has no dedicated human trials behind it at all.
Every human data point on thymosin alpha 1, from the sepsis meta-analysis to the cancer and hepatitis trials, comes from sick populations being treated for a specific diagnosed condition, not healthy people using it for general immune maintenance.
| Use case | Evidence tier | Human data? |
|---|---|---|
| Sepsis | Moderate | Yes |
| Cancer adjuvant (melanoma, NSCLC, HCC, breast, head & neck) | Moderate | Yes |
| Hepatitis B | Limited | Some |
| Hepatitis C | Limited | Some |
| HIV (adjunct with zidovudine/antiretrovirals) | Limited | Some |
| Vaccine adjuvant in elderly/immunocompromised | Limited | Some |
| Primary immune deficiency / DiGeorge syndrome | Limited | Very limited |
| COVID-19 / Long COVID | Emerging | Very limited |
| General wellness/"immune support" | Emerging | None |
Thymalfasin vs. Compounded thymosin alpha 1: What's the Difference?
Two products, one peptide name
Thymalfasin, sold under the brand Zadaxin, is the manufactured drug version of thymosin alpha 1. It’s produced to a defined specification, tested at a 2 mg/mL concentration in the clinical trials that support its approval, and sold as an approved pharmaceutical in 30+ countries.
Manufacturing consistency, batch testing, and regulatory oversight are built into how it reaches patients abroad.
Compounded thymosin alpha 1, as encountered in the US, is a different supply chain entirely. It’s prepared by compounding pharmacies rather than manufactured under the same drug-approval process, isn’t FDA-approved as a finished product, and is currently restricted under the Category 2 Bulk Drug Substances listing described above.
Because compounded versions aren’t standardized the way an approved drug is, there’s no guarantee that what’s dispensed matches the concentration, purity, or manufacturing controls behind the trial data discussed elsewhere in this article.
The concentration gap, made concrete
The clearest illustration of “same peptide, different product” is concentration itself: the FDA’s 2024 review flagged a proposed compounded concentration of 3 mg/mL, exceeding the 2 mg/mL tested in the trials that generated the peptide’s human safety and efficacy data.
A higher or otherwise non-matching concentration means the product hasn’t been studied at that strength, even though it shares the same peptide name.
Why this distinction matters practically
For a reader, this translates into real differences in sourcing, quality control, and legal standing: an internationally approved drug product carries manufacturing and regulatory guarantees that a compounded US product, under its current restricted status, does not.
Does thymosin alpha 1 Affect the Thyroid?
The short answer
No clinical or research source reviewed for this article documents a specific effect of thymosin alpha 1 on thyroid function, thyroid hormone levels (TSH, T3, T4), or thyroid autoimmunity. This isn’t a niche omission: none of the major reviews covering mechanism, clinical trial data, or safety profile mention the thyroid at all.
Absence of evidence isn’t evidence of absence
That silence in the literature doesn’t mean thymosin alpha 1 has been tested and found to have no thyroid effect. It means the question hasn’t been studied and reported in the sources available. There’s no basis here to claim a thyroid benefit, and equally no basis to claim a thyroid risk.
Anyone encountering a confident claim either way, in marketing material or elsewhere, should treat it as unsupported.
Why the question is plausible anyway
Thymosin alpha 1’s documented mechanisms involve T-cell maturation and modulation of cytokines like IL-2, IL-10, and IFN-gamma. Because autoimmune thyroid conditions such as Hashimoto’s thyroiditis involve T-cell-mediated immune activity, it’s reasonable to wonder whether an immune-modulating peptide could interact with thyroid autoimmunity in either direction.
But this connection is theoretical, drawn from general immunology rather than any thyroid-specific study of thymosin alpha 1. No trial, case report, or animal study in the reviewed research tests this link directly.
What this means in practice
Given that gap, anyone with existing thyroid disease, autoimmune or otherwise, considering thymosin alpha 1 has a reasonable case for discussing it with a physician first. That recommendation follows from the peptide’s broad immune-modulating mechanism and unknown interaction with autoimmune conditions generally, not from any documented thyroid-specific finding.
The History and Development of thymosin alpha 1
From calf thymus to a named peptide
Thymosin alpha 1 traces back to 1977, when Dr. Allan Goldstein and colleagues isolated it from calf thymus tissue, specifically a crude extract known as thymosin fraction 5. That extraction work laid the foundation for identifying the 28-amino-acid sequence as a distinct, biologically active peptide rather than a byproduct of the larger extract.
Mapping the structure
Later structural work characterized the peptide’s shape: a distorted helical configuration with an alpha-helix region spanning residues 14 through 26, and two beta-turns concentrated in the N-terminal 12 residues. Researchers also traced its biological origin, showing it is produced when the enzyme legumain cleaves prothymosin alpha, the larger parent molecule.
This gave the field a clear picture of both what the peptide looks like and where it comes from in the body.
From lab finding to approved drug
That research base eventually supported development into thymalfasin, the synthetic version now approved in 30+ countries under the brand name Zadaxin.
The research lineage
Two review papers anchor most of what’s summarized in this article: a 2020 comprehensive review (PMC7747025) covering clinical applications and dosing across disease states, and a 2010 mechanism-focused review (PMC7115394) detailing signaling pathways and receptor activity.
Alongside these, Li and colleagues’ sepsis meta-analysis and older hepatitis B trial data represent the human-trial evidence most frequently cited for this peptide.
A distinct peptide family
Thymosin alpha 1 belongs to a broader family of related molecules that are structurally or historically connected but biologically distinct. These include prothymosin alpha (its parent molecule), parathymosin, and the thymosin beta series (beta 4, 9, 10, 11, 12, and 15), which are involved in actin-binding and wound healing rather than immune modulation.
thymosin beta-4 These should not be confused with thymosin alpha 1 itself, even though they share a naming convention and a research origin.
Dosage and administration
Across every clinical source reviewed, thymosin alpha 1 is administered by subcutaneous injection. Reported doses and schedules vary by indication and by whether the source is a clinical trial or a clinic protocol. The table below summarizes what's been reported, not a recommendation for any individual.
How long is it actually taken for
Duration reported in the literature depends entirely on what's being treated. Hepatitis B and C trials ran participants on roughly 24-week schedules. Sepsis protocols, by contrast, involved much shorter courses tied to acute illness. Primary immune deficiency and DiGeorge syndrome use, where it exists, is described as ongoing and specialist-supervised rather than fixed-length.
None of the reviewed clinical literature establishes a standardized duration for general wellness or "immune support" use, because that use case has no dedicated human trials behind it in the first place.
In the US compounded market, providers have described periodic reassessment cycles, such as an 8-week refill period with a check-in after two refills or one year, as a way of structuring ongoing use.
This pattern reflects real-world compounding practice reported by at least one seller, not a clinical protocol or a recommendation, and it should be read as illustrative of how the gray-market product is currently being sold rather than evidence of an established or tested dosing schedule.
Reconstituted thymosin alpha 1 has been reported to require refrigerated storage over a matter of days, which is a practical handling detail rather than a dosing consideration, but it's worth knowing since improper storage could affect what's actually being injected.
None of the figures above are dosing instructions. They summarize what trials and clinic protocols have reported, and actual use of a compounded or foreign-approved product would depend on a provider's own assessment peptide therapy safety basics.
| Route | Subcutaneous injection |
| Dosage range | 0.8 mg to 6.4 mg per dose (commonly 1.6 mg) |
| Frequency | Twice weekly |
| Protocol | Cycles ranging from 5 to 7 days up to 24 weeks depending on use case |
| Form | Lyophilized powder, reconstituted before injection |
Safety and side effects
Across clinical trials, thymosin alpha 1 is generally described as well-tolerated, with adverse effects skewing mild rather than severe.
Most commonly reported
Injection site reactions are the most frequently cited side effect: irritation, redness, and discomfort at the point of subcutaneous injection. These are typically described as minor and self-limiting.
Also reported
Beyond injection site effects, trial and clinical reports note fatigue, flu-like symptoms, fever, and muscle aches. These appear less consistently than injection site reactions but show up across multiple disease-specific studies.
When combined with interferon
When thymosin alpha 1 is paired with interferon-alpha, as in older hepatitis B and C protocols, additional side effects emerge: nausea, vomiting, and occasionally neutropenia (a drop in a type of white blood cell).
It’s not always clear from trial data how much of this profile comes from the interferon component versus the peptide itself, since these studies tested the combination rather than thymosin alpha 1 alone.
The long-term data gap
Nearly all available safety data comes from short-to-medium duration, disease-specific trials, patients treated for weeks to months for sepsis, hepatitis, or as a cancer adjuvant. No published human research tracks multi-year use in the way a longevity or general wellness protocol would involve.
This is a real and unaddressed gap for anyone considering ongoing use outside a specific medical indication.
A concrete example of the dosing gap
The FDA’s own review flagged a related concern: proposed US compounding concentrations of 3 mg/mL exceed the 2 mg/mL concentration actually studied in clinical trials. That means the version potentially available through US compounding pharmacies could differ, at the concentration level, from the formulations that generated the existing safety and efficacy data.
This isn’t a theoretical nitpick; it’s the specific rationale a 2024 FDA advisory panel cited in declining to expand access compounded peptides and US law.
Who should not use Thymosin Alpha-1
Who Should NOT Use thymosin alpha 1?
Because thymosin alpha 1 works by activating immune pathways, not suppressing them, the populations where it’s most likely to cause harm are the mirror image of who it might help. A handful of groups come up consistently in the research and clinical framing.
Known hypersensitivity to the compound. This is treated as an absolute contraindication in the clinical literature. Anyone with a documented allergic reaction to thymosin alpha 1 or thymalfasin should not be re-exposed, full stop.
Organ transplant recipients and other immunosuppressed patients. This is contraindicated unless a specialist has determined the benefit outweighs the risk. The mechanism explains why: transplant patients rely on suppressed T-cell and immune activity to prevent organ rejection, and a peptide designed to stimulate T-cell maturation and cytokine production works directly against that goal.
This isn’t a case where “boost immunity” is a neutral or automatically positive framing.
Pregnancy. The research notes that natural Tα1 levels rise during pregnancy, but that’s a physiological observation, not a safety finding for supplemental use. No source in the clinical literature establishes safety data for administering exogenous thymosin alpha 1 during pregnancy.
This is an evidence gap, not a proven danger, and it should be treated with the caution that gap implies rather than dismissed.
Autoimmune disease. Clinic marketing pages sometimes describe benefit for autoimmune conditions, but these claims aren’t backed by the same trial rigor as the sepsis or cancer data.
Given that the peptide’s core mechanism is immune activation, someone with an already dysregulated or overactive immune system has real reason to want specialist input before use, not a marketing page’s word for it.
No consolidated list exists. No single source in the available literature, including the highest-authority reviews, provides a complete, formal contraindication list. That gap is worth stating plainly rather than papering over: physician screening before use is the practical substitute for a list that doesn’t yet exist.
Legal status
The short answer
Thymosin alpha 1 is not FDA-approved in the United States. As thymalfasin, it is approved under the brand name Zadaxin in more than 30 countries, and it has been used in China since April 2020 as part of COVID-19 treatment protocols.
In the US, it exists in a gray zone: not an approved drug, but until recently something compounding pharmacies could legally prepare.
What changed in late 2023
In late 2023, the FDA added thymosin alpha 1 to its Category 2 Bulk Drug Substances list. In plain English, Category 2 means the FDA has identified safety or quality concerns significant enough to bar compounding pharmacies from using the substance while it undergoes further review.
This is not an outright ban on the molecule, but it does mean licensed US compounders can no longer legally prepare it for patients, which is the primary channel through which US consumers had been accessing it.
The 2024 panel review
In 2024, an FDA advisory panel voted against moving thymosin alpha 1 back to Category 1 (the less restricted list). The panel's stated concerns centered on manufacturing stability and a proposed compounding concentration of 3 mg/mL, which exceeds the 2 mg/mL concentration actually tested in the clinical trials underlying the international drug's safety data.
In effect, the compounding formulation under review did not match what had been studied.
What's next
A new advisory panel review was announced for 2026, with sessions scheduled for July 23–24, 2026. Thymosin alpha 1 specifically is expected to come up for discussion in a 2027 session rather than the initial July 2026 sessions. Nothing about current restrictions changes until that review concludes, if it changes at all.
Why this matters for readers right now
This regulatory picture is a snapshot, not a permanent fact. The Category 2 listing, the 2024 rejection, and the pending 2026/2027 review are all specific to a narrow window in time, and the outcome of the next panel session could shift what's legally available through US compounding pharmacies.
Anyone weighing access to thymosin alpha 1 in the US should verify the current FDA Bulk Drug Substances list status directly rather than relying on a fixed answer, since this is one of the more time-sensitive facts in this entire guide. immune-modulating peptides compared
| FDA status | Not FDA-approved for any indication in the US. Approved as thymalfasin (Zadaxin) in 30+ countries including China, not in the US. |
| Compounding status | Added to FDA Category 2 Bulk Drug Substances list in late 2023, barring compounding pharmacies from using it. A 2024 FDA advisory panel voted against restoring Category 1 status, citing manufacturing stability concerns and a proposed 3 mg/mL compounding concentration exceeding the 2 mg/mL tested in trials. New advisory panel sessions held July 23-24, 2026, with thymosin alpha-1 specific review expected in 2027. |
| Anti-doping | Not separately listed as a named substance on the WADA Prohibited List; peptide immunomodulators of this type fall under general scrutiny but no explicit ruling found in sourced research. |
| Controlled substance | Not a scheduled/controlled substance under US federal law. |
| Access pathway | Legitimate access in the US currently limited to clinical trial participation or off-label physician-directed use of internationally sourced thymalfasin; routine compounded sales are not permitted under current Category 2 status pending 2027 FDA review. |
Often used with
These are the compounds that actually appear alongside thymosin alpha 1 in the clinical trial record, not a list of things to combine it with. Each was studied as part of a specific disease protocol, and the pairing reflects trial design, not a general stacking strategy. Interferon-alpha (2a/2b, pegylated), Moderate Interferon-alpha, including pegylated forms, was the combination partner in the hepatitis B and C trials and part of the 488-patient melanoma trial alongside dacarbazine. Researchers
Interferon-alpha (2a/2b, pegylated)
ModerateAn antiviral immune-signaling protein used clinically alongside thymosin alpha 1 in hepatitis B and C protocols, where the two were combined to boost virologic response rates in trial settings.
View Interferon-alpha (2a/2b, pegylated) →Thymosin Beta 4
LimitedA related but structurally distinct thymic peptide known for tissue repair and wound healing rather than immune modulation; often mentioned together with thymosin alpha 1 due to shared naming and thymic origin, though they serve different purposes.
View Thymosin Beta 4 →Dacarbazine
LimitedA chemotherapy agent studied in combination with thymosin alpha 1 and interferon alpha for metastatic melanoma, reflecting its historical role as a cancer-adjuvant pairing.
View Dacarbazine →Lamivudine / Entecavir
LimitedNucleoside analog antivirals used alongside thymosin alpha 1 in older chronic hepatitis B regimens, now largely superseded by direct-acting antivirals.
View Lamivudine / Entecavir →Frequently asked questions
Who should not take thymosin alpha 1?
Avoid it if you have known hypersensitivity to the peptide. Organ transplant recipients and other immunosuppressed patients should only use it under specialist supervision, since it stimulates immune activity that could affect graft tolerance. Pregnant or breastfeeding individuals lack safety data.
What are the side effects of thymosin?
Most commonly injection site redness, swelling, or discomfort. Some users report mild fatigue, flu-like symptoms, fever, or muscle aches, especially when combined with interferon. Nausea and vomiting are less common. Serious adverse effects are rare in published trials.
Does thymosin alpha 1 affect the thyroid?
No published clinical research documents a direct effect on thyroid function. This isn't a confirmed risk or benefit in the literature. If you have thyroid disease, discuss any peptide use with your doctor before starting, since data specifically on this question doesn't exist yet.
How long should I take thymosin alpha 1?
Duration depends entirely on the reason for use. Clinical trials for hepatitis B ran about 24 weeks; sepsis protocols used shorter courses of days. There's no established timeline for general wellness use. Compounded protocols often reassess every 8 weeks.
Is thymosin alpha 1 legal in the US?
It isn't FDA-approved for any condition. In late 2023, the FDA placed it on the Category 2 Bulk Drug Substances list, restricting compounding pharmacies from making it. An advisory panel rejected reinstating broader access in 2024, with further review expected in 2026 to 2027.
What's the difference between thymalfasin and compounded thymosin alpha 1?
Thymalfasin (Zadaxin) is the pharmaceutical-grade version approved in over 30 countries internationally, though not by the FDA in the US., though not the US. Compounded thymosin alpha 1 is made by US pharmacies without FDA approval, using non-standardized concentrations, some exceeding what was ever tested in clinical trials.
Does thymosin alpha 1 work for long COVID?
Evidence is preliminary. China used it during acute COVID-19 treatment starting in 2020, and its immune-modulating mechanism is plausible for long COVID symptoms, but no rigorous trials confirm effectiveness for long COVID specifically. Current support relies on anecdote, not controlled studies.
Is thymosin alpha 1 still used for hepatitis B or C?
Rarely in current practice. It showed real benefit in older trials, improving viral response rates, but direct-acting antivirals now treat hepatitis B and C more effectively and are standard of care. Thymosin alpha 1 for these conditions is largely historical.
Sources
- Ancell CD, Phipps J, Young L (2001). Thymosin alpha-1. American Journal of Health-System Pharmacy link
- Dominari A, Hathaway D, et al. (2020). Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology link
- Matteucci C, Grelli S, Balestrieri E (2017). Thymosin alpha 1 and HIV-1: recent advances and future perspectives. Future Microbiology link
- Wei Y, Zhang Y, Li P (2023). Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International Immunopharmacology link
- Soeroto AY, Suryadinata H, Yanto TA (2023). The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Inflammopharmacology link
- Simonova MA, Ivanov I, Shoshina NS (2025). Aging and Thymosin Alpha-1. International Journal of Molecular Sciences link
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA.gov link